Spexis AG
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class therapeutics for rare diseases and oncology. The company leverages its proprietary technology platform centered on macrocyclic molecules to create novel treatments. Its development pipeline primarily targets indications in rare, chronic respiratory diseases, such as cystic fibrosis, as well as heme-oncology. Formerly known as Polyphor AG, Spexis is advancing its portfolio to address significant unmet medical needs in its core therapeutic areas.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-11-05 07:15 |
Delisting Announcement
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
|
English | 9.3 KB | ||
| 2024-11-05 01:00 |
Delisting Announcement
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
|
English | 7.7 KB | ||
| 2024-07-29 07:15 |
Legal Proceedings Report
Spexis granted definitive moratorium status until 25 November 2024, subject to …
|
English | 8.6 KB | ||
| 2024-07-29 02:00 |
Legal Proceedings Report
Spexis granted definitive moratorium status until 25 November 2024, subject to …
|
English | 6.9 KB | ||
| 2024-07-22 07:15 |
Legal Proceedings Report
Spexis expects that audit of its 2023 financials will not be completed by 31 Ju…
|
English | 10.8 KB | ||
| 2024-07-22 02:00 |
Legal Proceedings Report
Spexis expects that audit of its 2023 financials will not be completed by 31 Ju…
|
English | 9.1 KB | ||
| 2024-07-08 07:15 |
Legal Proceedings Report
Spexis AG: PARI Pharma GmbH announces termination of ColiFin license to EnBioti…
|
English | 10.0 KB | ||
| 2024-07-08 02:00 |
Legal Proceedings Report
Spexis AG: PARI Pharma GmbH announces termination of ColiFin® license to EnBiot…
|
English | 8.4 KB | ||
| 2024-06-04 20:00 |
Delisting Announcement
Spexis launches appeal against SIX Exchange Regulation decision to suspend trad…
|
English | 8.0 KB | ||
| 2024-06-04 02:00 |
Delisting Announcement
Spexis launches appeal against SIX Exchange Regulation decision to suspend trad…
|
English | 6.4 KB | ||
| 2024-05-31 22:00 |
Report Publication Announcement
Spexis receives second extension for the publication of its 2023 annual report …
|
English | 19.4 KB | ||
| 2024-05-31 02:00 |
Report Publication Announcement
Spexis receives second extension for the publication of its 2023 annual report …
|
English | 16.6 KB | ||
| 2024-04-30 20:30 |
Report Publication Announcement
Spexis receives approval of an extension of the deadline for the publication of…
|
English | 9.8 KB | ||
| 2024-04-30 02:00 |
Report Publication Announcement
Spexis receives approval of an extension of the deadline for the publication of…
|
English | 8.2 KB | ||
| 2024-04-17 07:15 |
Regulatory News Service
Spexis announces extension of moratorium, receipt of an additional payment rela…
|
English | 13.8 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
